Epithelial Ovarian Cancer - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 382 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epithelial Ovarian Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Epithelial Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Epithelial Ovarian Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Epithelial Ovarian Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Epithelial Ovarian Cancer - Overview 11
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 12
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 13
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 18
Epithelial Ovarian Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Epithelial Ovarian Cancer - Products under Development by Companies 22
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 27
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
Adaptimmune Limited 29
Amgen Inc. 30
Astex Pharmaceuticals, Inc. 31
AstraZeneca PLC 32
Bayer AG 33
Bionomics Limited 34
BioNumerik Pharmaceuticals, Inc. 35
Boehringer Ingelheim GmbH 36
Celldex Therapeutics, Inc. 37
Celon Pharma Sp. z o.o. 38
Celsion Corporation 39
Cerulean Pharma, Inc. 40
Clovis Oncology, Inc. 41
Eli Lilly and Company 42
Exelixis, Inc. 43
F. Hoffmann-La Roche Ltd. 44
Genentech, Inc. 45
Glycotope GmbH 46
ImmunoGen, Inc. 47
Immunotope, Inc. 48
Johnson & Johnson 49
MabVax Therapeutics Holdings, Inc. 50
Merck & Co., Inc. 51
Millennium Pharmaceuticals, Inc. 52
NeoStem, Inc. 53
Novartis AG 54
Oasmia Pharmaceutical AB 55
OBI Pharma, Inc. 56
Oncobiologics, Inc. 57
Oncolytics Biotech Inc. 58
Onxeo SA 59
Otsuka Holdings Co., Ltd. 60
Oxford BioMedica plc 61
OXiGENE, Inc. 62
Pfizer Inc. 63
Pharma Mar, S.A. 64
Pharmacyclics, Inc. 65
Prima BioMed Ltd. 66
PsiOxus Therapeutics, Ltd. 67
Sanofi 68
Sanofi Pasteur SA 69
Sotio a.s. 70
Synta Pharmaceuticals Corp. 71
Tesaro, Inc. 72
TetraLogic Pharmaceuticals 73
Therapeutic Proteins International, LLC 74
TRACON Pharmaceuticals, Inc. 75
VentiRx Pharmaceuticals, Inc. 76
Epithelial Ovarian Cancer - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Target 78
Assessment by Mechanism of Action 82
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
abexinostat hydrochloride - Drug Profile 89
abiraterone acetate - Drug Profile 92
ABT-898 - Drug Profile 95
alisertib - Drug Profile 96
anetumab ravtansine - Drug Profile 100
Antisense Oligonucleotide for Ovarian and Colorectal Cancer - Drug Profile 102
AZD-1775 - Drug Profile 103
belinostat - Drug Profile 105
bevacizumab - Drug Profile 108
bevacizumab biosimilar - Drug Profile 113
bevacizumab biosimilar - Drug Profile 114
bevacizumab biosimilar - Drug Profile 115
birinapant - Drug Profile 116
BNC-105P - Drug Profile 119
cabozantinib s-malate - Drug Profile 121
Cancer Stem Cell Therapy - Drug Profile 124
catumaxomab - Drug Profile 125
CDX-1401 - Drug Profile 127
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 129
cositecan - Drug Profile 131
CRLX-101 - Drug Profile 133
CVac - Drug Profile 135
DCVAC/OvCa - Drug Profile 138
DMUC-4064A - Drug Profile 139
EGEN-001 - Drug Profile 140
elesclomol - Drug Profile 142
enadenotucirev - Drug Profile 144
erismodegib - Drug Profile 146
fosbretabulin tromethamine - Drug Profile 149
ganetespib - Drug Profile 153
guadecitabine - Drug Profile 157
IMT-1012 - Drug Profile 160
LCL-161 - Drug Profile 161
lifastuzumab vedotin - Drug Profile 163
lurbinectedin - Drug Profile 165
LY-2606368 - Drug Profile 168
MesoCART - Drug Profile 169
mirvetuximab soravtansine - Drug Profile 170
motolimod - Drug Profile 172
NERX-313E - Drug Profile 174
NERX-505X - Drug Profile 175
nintedanib - Drug Profile 176
niraparib - Drug Profile 181
NSC-748933 - Drug Profile 183
OBI-822/821 - Drug Profile 184
OPB-111001 - Drug Profile 186
paclitaxel - Drug Profile 187
PankoMab-GEX - Drug Profile 189
pelareorep - Drug Profile 190
pembrolizumab - Drug Profile 195
PF-06647263 - Drug Profile 202
Procure - Drug Profile 203
Protein to Antagonize Frizzled Receptors for Epithelial Ovarian Cancer - Drug Profile 204
ralimetinib mesylate - Drug Profile 205
regorafenib - Drug Profile 206
rucaparib phosphate - Drug Profile 209
SAR-408701 - Drug Profile 212
sorafenib tosylate - Drug Profile 213
trabectedin - Drug Profile 217
TRC-105 - Drug Profile 221
trebananib - Drug Profile 224
TroVax - Drug Profile 227
Vaccine for Oncology - Drug Profile 230
Vaccine to Target Carcinoembryonic Antigen for Oncology - Drug Profile 231
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile 232
Vaccine to Target IGFBP-2 for Epithelial Ovarian Cancer - Drug Profile 233
varlilumab - Drug Profile 234
vCP-2292 - Drug Profile 236
X-82 - Drug Profile 237
Epithelial Ovarian Cancer - Recent Pipeline Updates 239
Epithelial Ovarian Cancer - Dormant Projects 368
Epithelial Ovarian Cancer - Discontinued Products 370
Epithelial Ovarian Cancer - Product Development Milestones 371
Featured News & Press Releases 371
Appendix 376
Methodology 376
Coverage 376
Secondary Research 376
Primary Research 376
Expert Panel Validation 376
Contact Us 376
Disclaimer 377

List of Tables

Number of Products under Development for Epithelial Ovarian Cancer, H1 2015 16
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Development by Companies, H1 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2015 33
Epithelial Ovarian Cancer - Pipeline by Adaptimmune Limited, H1 2015 34
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2015 35
Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 36
Epithelial Ovarian Cancer - Pipeline by AstraZeneca PLC, H1 2015 37
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2015 38
Epithelial Ovarian Cancer - Pipeline by Bionomics Limited, H1 2015 39
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 40
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 41
Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 42
Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2015 43
Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H1 2015 44
Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 45
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2015 46
Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2015 47
Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2015 48
Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 49
Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H1 2015 50
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2015 51
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2015 52
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H1 2015 53
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2015 54
Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 55
Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H1 2015 56
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 57
Epithelial Ovarian Cancer - Pipeline by NeoStem, Inc., H1 2015 58
Epithelial Ovarian Cancer - Pipeline by Novartis AG, H1 2015 59
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 60
Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H1 2015 61
Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H1 2015 62
Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 63
Epithelial Ovarian Cancer - Pipeline by Onxeo SA, H1 2015 64
Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 65
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H1 2015 66
Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H1 2015 67
Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H1 2015 68
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2015 69
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 70
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2015 71
Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 72
Epithelial Ovarian Cancer - Pipeline by Sanofi, H1 2015 73
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2015 74
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2015 75
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 76
Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H1 2015 77
Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015 78
Epithelial Ovarian Cancer - Pipeline by Therapeutic Proteins International, LLC, H1 2015 79
Epithelial Ovarian Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 80
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 81
Assessment by Monotherapy Products, H1 2015 82
Number of Products by Stage and Target, H1 2015 84
Number of Products by Stage and Mechanism of Action, H1 2015 88
Number of Products by Stage and Route of Administration, H1 2015 91
Number of Products by Stage and Molecule Type, H1 2015 93
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2015 244
Epithelial Ovarian Cancer - Dormant Projects, H1 2015 373
Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H1 2015 374
Epithelial Ovarian Cancer - Discontinued Products, H1 2015 375